Table 4 ECV changes in RT-induced MCT studies using MRI (No decrease of ECV was reported)

Van Der Velde et al.,[50]

80

HL&

NHL

-

No differences with healthy control

at 20 years post-RT

(28±3% vs 29±3%, p=0.24)

-

Bergom et al., [48]

20

Breast

-

Mean global ECV of 27%

(range: 23-34%) at 8.3 years

post-RT

-

Takagi et al., [57]

24

Esophagus

In basal septum

(high radiated area, 43±4 Gy) in 0.5 year follow up

(26±3% vs 32±3%, P<0.01)

-

-

Tahir et al., [55]

66

Breast

-

In epirubicin-chemotherapy-based

followed by RT group:

(Baseline: 28±2% and

13±2 months: 29±2%, p=0.52)

-

-

In left-seded RT only group:

(baseline: 30±3% and

13±2 months: 30±3%)

-

de Groot et al., [63]

40

Esophagus

(28.4±1.0% vs 24.0±0.9%; P<0.001)

-

Linear relation between mean dose per segment and ECV increase

(a 0.136%-point increase of ECV for each Gy (P<0.001) at 67.6 months

Canada et al., [65]

30

Chest malignancies

no associations with dose:

median 28% [26,27,28,29,30,31]

at 2 years post-RT

-

Mukai-Yatagai et al., [64]

1

Esophagus

Increase of ECV (45%) at 8 years

-

-

Vallabhaneni et al., [54]

11

Lung, breast, lymphoma

-

No significant % ECV changes in patients with higher radiation

(-11.5±20.8%) or patients with minimal radiation (-8.1±2.9%)

at 6-months following RT

-